Sustainability | May 08, 2025
Granules India bags EcoVadis’ Gold Rating
The company's first-ever corporate-level submission to EcoVadis builds on years of operational and environmental excellence
The company's first-ever corporate-level submission to EcoVadis builds on years of operational and environmental excellence
The portfolio consists of liquids and immediate release solid orals which are in the therapeutic segment to treat infections associated with UTIs
The FDA issued Form 483 with one observation related to building and facility management
Phesgo label expansion delivers on patients’ preference for at-home administration and is an important step in freeing up cancer care capacity in clinical settings
The Subsidiary has received one inspectional observation in Form 483
Investment demonstrates confidence in America’s commitment to science and innovation
The inspection concluded with 6 observations and none of them were related to Data Integrity
Trastuzumab specifically binds and inhibits the human epidermal growth factor receptor 2 (HER2) protein
The new facility combines advanced technology, enhanced capacity, and holistic care, reaffirming HCG’s commitment to accessible, world-class oncology in Gujarat
DESTINY-Breast09 Phase III trial of AstraZeneca and Daiichi Sankyo’s Enhertu is the first trial in more than a decade to demonstrate superior efficacy across a broad HER2-positive metastatic patient population versus current 1st-line standard of care
Subscribe To Our Newsletter & Stay Updated
